AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27018419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 24840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during bow-and-arrow exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during external-rotation-with-scapular-squeeze exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants during bow-and-arrow exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants during external-rotation-with-scapular-squeeze exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during lawnmower exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants during lawnmower exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with GH injuries during robbery exercise
Number of subjects: 39
Study 24840585 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants during robbery exercise
Number of subjects: 39
Study 22305276 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (2000mg/day)
Number of subjects: 53
Study 22305276 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (6000mg/day)
Number of subjects: 53
Study 22305276 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (varied doses)
Number of subjects: 53
Study 20202684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/day fluocinolone acetonide intravitreal insert
Number of subjects: 37
Study 20202684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg/day fluocinolone acetonide intravitreal insert
Number of subjects: 37
Study 17888192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (Group A)
Number of subjects: 240
Study 17888192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine + 10 mL saline epidurally (Group B)
Number of subjects: 240
Study 17888192 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine (Group C)
Number of subjects: 240
Study 17888192 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine + 10 mL saline epidurally (Group D)
Number of subjects: 240
Study 17888192 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A and B)
Number of subjects: 240
Study 15987848 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Ascorbic Acid (AA) twice daily for 6 days
Number of subjects: 48
Study 15987848 — intervention group
Group type: COMPARATOR
Intervention: No Ascorbic Acid (AA) for 6 days
Number of subjects: 48
Study 12622584 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) 80 ppm with 21% final concentration of inspired oxygen (n=10)
Number of subjects: 20
Study 12622584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (21% inspired oxygen; n=10)
Number of subjects: 20
Study 10582983 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg po daily) for 6 weeks
Number of subjects: 394
Study 10582983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 8915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 161
Study 8915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (1, 3, or 5 mg)
Number of subjects: 161
Study 8915035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 1801536 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 5
Study 1801536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6188770 — intervention group
Group type: EXPERIMENTAL
Intervention: Local terbutaline (nontoxic doses)
Number of subjects: 0
Study 6188770 — intervention group
Group type: COMPARATOR
Intervention: Control (antigen challenge without terbutaline)
Number of subjects: 0
Study 30267032 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA 101 vaccine (100 μg/peptide) given subcutaneously on days 1, 22, and 50; Nivolumab (3 mg/kg) given intravenously every 2 weeks starting day 8 for up to 1 year
Number of subjects: 24
Study 29294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial catheter placement
Number of subjects: 500
Study 29294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Last CT prior to randomization
Number of subjects: 500
Study 29294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter placement accuracy
Number of subjects: 500
Study 29294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operating room catheter placement
Number of subjects: 500
Study 29294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-admission use of antiplatelet drugs
Number of subjects: 500
Study 26724834 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) during induction and/or maintenance therapy
Number of subjects: 240
Study 26724834 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 240
Study 24316679 — intervention group
Group type: EXPERIMENTAL
Intervention: NeReBot therapy (robotic training 35% of exercise time) + standard therapy (65% of exercise time)
Number of subjects: 34
Study 24316679 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for the upper limb (control group)
Number of subjects: 34
Study 22584796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenously four times daily) and fludrocortisone (50 μg orally once daily)
Number of subjects: 299
Study 22584796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 299
Study 20172512 — intervention group
Group type: COMPARATOR
Intervention: Conventional TESE
Number of subjects: 335
Study 20172512 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdissection TESE
Number of subjects: 335
Study 20172512 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 335
Study 18001380 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 0
Study 18001380 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt
Number of subjects: 0
Study 15149708 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week cognitive-behavioral group intervention
Number of subjects: 23
Study 15149708 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 23
Study 11771665 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor) for 6 months
Number of subjects: 42
Study 11771665 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 42
Study 9659199 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 23
Study 9659199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8131700 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once a day for 5 days
Number of subjects: 8
Study 8131700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms three times a day for 5 days
Number of subjects: 8
Study 8131700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omeprazole and enprostil
Number of subjects: 8
Study 8131700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2563786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake group (53 subjects; diet containing less than 80 mmol sodium/day plus 8 placebo tablets daily)
Number of subjects: 111
Study 2563786 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium intake group (55 subjects; same dietary sodium plus 8 slow-release sodium chloride [10 mmol] tablets daily)
Number of subjects: 111
Study 31513759 — intervention group
Group type: EXPERIMENTAL
Intervention: Wahakura (a bassinet-like device made of native flax)
Number of subjects: 0
Study 31513759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pēpi-Pod (related safe sleep device)
Number of subjects: 0
Study 31513759 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (general intervention context)
Number of subjects: 0
Study 27821375 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 384
Study 27821375 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stent (CoCr-EES)
Number of subjects: 384
Study 26180559 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil
Number of subjects: 130
Study 26180559 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study 24280617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of botulinum toxin A (BoNT/A)
Number of subjects: 12
Study 24280617 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency (MFR) therapy
Number of subjects: 12
Study 24280617 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 12
Study 24280617 — intervention group
Group type: COMPARATOR
Intervention: BoNT/A injection side
Number of subjects: 12
Study 21680997 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ (150 mg/12.5 mg titrated to 300 mg/25 mg)
Number of subjects: 1268
Study 21680997 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (150 mg titrated to 300 mg)
Number of subjects: 1268
Study 21680997 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Number of subjects: 1268
Study 21680997 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 1268
Study 21680997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1268
Study 18804918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 297
Study 15940534 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude (2,650 m)
Number of subjects: 14
Study 10483629 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 114
Study 10483629 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga stretching
Number of subjects: 114
Study 10483629 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 114
Study 10483629 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study 8597317 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin, 80 mg/d
Number of subjects: 188
Study 8597317 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 188
Study 1822427 — intervention group
Group type: EXPERIMENTAL
Intervention: Full inpatient treatment
Number of subjects: 266
Study 1822427 — intervention group
Group type: EXPERIMENTAL
Intervention: Day center treatment
Number of subjects: 266
Study 1822427 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-in clinic treatment
Number of subjects: 266
Study 1822427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterical syndrome
Number of subjects: 266
Study 1822427 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychasthenic syndrome
Number of subjects: 266
Study 1822427 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of the therapeutic programmes
Number of subjects: 266
Study 6752585 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 38
Study 6752585 — intervention group
Group type: COMPARATOR
Intervention: mitomycin C
Number of subjects: 38
Study 30870040 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Power Training (MPT)
Number of subjects: 12
Study 31595295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish consumption (∼300 g/wk)
Number of subjects: 199
Study 31595295 — intervention group
Group type: COMPARATOR
Intervention: Poultry consumption (control group)
Number of subjects: 199
Study 28871896 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided intervention
Number of subjects: 194
Study 28871896 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported-guided intervention
Number of subjects: 194
Study 26830711 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week simulation curriculum (Group A)
Number of subjects: 0
Study 26830711 — intervention group
Group type: COMPARATOR
Intervention: 7-week lecture curriculum (Group B)
Number of subjects: 0
Study 24702572 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 104
Study 24702572 — intervention group
Group type: COMPARATOR
Intervention: Standard phacoemulsification
Number of subjects: 104
Study 22938185 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, discrete event simulations
Number of subjects: 11
Study 20124504 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized special nursery placement
Number of subjects: 33
Study 20124504 — intervention group
Group type: EXPERIMENTAL
Intervention: Special nursery placement solely for children with ASDs
Number of subjects: 33
Study 20124504 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based 1:1 programme
Number of subjects: 33
Study 17950797 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) (200 mg/day)
Number of subjects: 44
Study 17950797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15766818 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 4 mg/day)
Number of subjects: 57
Study 15766818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11990868 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif-Serono)
Number of subjects: 52
Study 10557167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride drops (0.25 mg for 2-3 year-olds, 0.5 mg for older children) taken daily for 3 years
Number of subjects: 176
Study 10557167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride drops)
Number of subjects: 176
Study 8575054 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium (0.3 mg/kg)
Number of subjects: 40
Study 8575054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 40
Study 8575054 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium and Pancuronium
Number of subjects: 40
Study 2199681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice a day)
Number of subjects: 140
Study 31932574 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous polyoxymethylene thermoplastic regulator combined with a 3D printed template
Number of subjects: 40
Study 31932574 — intervention group
Group type: COMPARATOR
Intervention: Conventional PPSF
Number of subjects: 40
Study 31932574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 31106415 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Friendly Spaces (CFS) attendance
Number of subjects: 430
Study 31106415 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Friendly Spaces (CFS) attendance (higher quality programming)
Number of subjects: 430
Study 31106415 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Friendly Spaces (CFS) attendance (higher quality programming for boys)
Number of subjects: 430
Study 31106415 — intervention group
Group type: COMPARATOR
Intervention: CFS attendance
Number of subjects: 430
Study 28213908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) 400 mg at a rate of 60 mg/kg/min
Number of subjects: 66
Study 25727903 — intervention group
Group type: EXPERIMENTAL
Intervention: High in milk diet
Number of subjects: 15
Study 25727903 — intervention group
Group type: EXPERIMENTAL
Intervention: High in cheese diet
Number of subjects: 15
Study 25727903 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 15
Study 24164102 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid treatment
Number of subjects: 60
Study 22288723 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser transscleral cyclophotocoagulation (TSCP)
Number of subjects: 8
Study 22288723 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (untreated)
Number of subjects: 8
Study 20070800 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 0
Study 20070800 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PBL intervention
Number of subjects: 0
Study 20070800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple PBL interventions
Number of subjects: 0
Study 17557777 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 125
Study 17557777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16386537 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg) and vitamin B12 (500 mg) daily for 3 months
Number of subjects: 70
Study 12048040 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg/kg of phenytoin
Number of subjects: 7
Study 12048040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10461765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 10
Study 10461765 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg)
Number of subjects: 10
Study 10461765 — intervention group
Group type: COMPARATOR
Intervention: Lactate capsule (Control)
Number of subjects: 10
Study 7609265 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antiendotoxin antibody
Number of subjects: 100
Study 2507435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP, 10 mg orally 3 times daily for 7 days)
Number of subjects: 24
Study 2507435 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated LP)
Number of subjects: 24
Study 2507435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP)
Number of subjects: 24
Study 324556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine (1 g in 2 ml of water)
Number of subjects: 410
Study 324556 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (1 g in 2 ml of water)
Number of subjects: 410
Study 324556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine
Number of subjects: 410
Study 324556 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 410
Study 31332655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided therapy (semi-quantitative evaluation of B lines and the presence of pleural effusion)
Number of subjects: 0
Study 31332655 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (clinical assessment of congestion)
Number of subjects: 0
Study 28395844 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (100 mg/20 mg once daily until age 6 months and 200 mg/40 mg once daily thereafter)
Number of subjects: 2848
Study 28395844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2848
Study 28395844 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 2848
Study 26057427 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day hospice experience
Number of subjects: 61
Study 23075046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 72 mg with fentanyl 10 μg (Group A + F)
Number of subjects: 100
Study 23075046 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric articaine 72 mg without fentanyl (Group A)
Number of subjects: 100
Study 22122992 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 70
Study 22122992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19317864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine infused at 8.4 ml/h (low concentration group, n=35)
Number of subjects: 70
Study 19317864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine infused at 1.4 ml/h (high concentration group, n=35)
Number of subjects: 70
Study 17369566 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously on day 1 only)
Number of subjects: 40
Study 17369566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15479682 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli Nissle 1917, 200 mg once daily (n = 162)
Number of subjects: 327
Study 15479682 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine, 500 mg three times daily (n = 165)
Number of subjects: 327
Study 11903415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 37
Study 11903415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9390616 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% in new formulation
Number of subjects: 24
Study 9390616 — intervention group
Group type: COMPARATOR
Intervention: Standard propofol formulation
Number of subjects: 24
Study 8201393 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape of the consultation followed 7 to 10 days later by the letter
Number of subjects: 182
Study 8201393 — intervention group
Group type: COMPARATOR
Intervention: Individualized summary letters followed by the audiotape
Number of subjects: 182
Study 3310725 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in 30% O2/70% N2
Number of subjects: 40
Study 3310725 — intervention group
Group type: COMPARATOR
Intervention: Halothane in 30% O2/70% N2O
Number of subjects: 40
Study 31810405 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation, education, and exercise
Number of subjects: 90
Study 31810405 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation, education, and exercise
Number of subjects: 90
Study 29382251 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment for nodding syndrome
Number of subjects: 0
Study 26975947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 60
Study 26975947 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 60
Study 26975947 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP
Number of subjects: 60
Study 26275982 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (metoprolol and carvedilol)
Number of subjects: 60
Study 26275982 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (diltiazem and verapamil)
Number of subjects: 60